Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Moxetumomab Pasudotox in Pediatric Relapsed/Refractory B-cell ALL/Lymphoma
NCT02227108Phase 2Terminated
- Sponsor
- MedImmune
- Start
- Aug 2014
- Primary completion
- Nov 2015
- Modality
- Antibody Fragments, Immunotoxins, Monoclonal Antibodies
- Countries
- 8
01
Overview
Phase 2, open-label, single-arm trial of moxetumomab pasudotox in B cell acute lymphoblastic leukemia (B-ALL) and B-cell lymphoblastic lymphoma (B-LBL), sponsored by MedImmune. Primary endpoint: Percentage of Participants With Composite Complete Response (CRc) up to 1 year. Started Aug 2014; status: terminated.
02
Drugs
moxetumomab pasudotox
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)B-cell lymphoblastic lymphoma (B-LBL)
Beyond the preview
Go deeper on NCT02227108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02227108.